TAVR

Transcatheter aortic valve replacement (TAVR) is a key structural heart procedure that has rapidly expanded in the decade since it was first FDA cleared. TAVR has come a paradigm shift in how many aortic stenosis patients are treated, now making up more than 50% of U.S. aortic valve replacements. It is less invasive than open heart surgery and recovery times are greatly reduced. TAVR can also be used in patients who otherwise are too high risk to undergo surgery. TAVR is referred to as transcatheter aortic valve implantation (TAVI) in many placed outside of the U.S. TAVR inspired the growing areas of transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

RSS icon
Thumbnail

Skip the clopidogrel? TAVR patients benefit from antiplatelet therapy that includes aspirin only

The risk of major bleeding or life-threatening bleeding events was higher when clopidogrel was included in the patient's treatment strategy. 

Boston Scientific to retire Lotus Edge TAVR program after voluntary recall

The company will now focus its attention on the marketing and development of other solutions.

Thumbnail

TAVR stands tall as ‘the dominant form of aortic valve replacement,’ specialty groups declare

Specialists from the American College of Cardiology and Society of Thoracic Surgeons explored data from more than 276,000 patients who have undergone a TAVR procedure in the last nine years. 

Thumbnail

Wait times for TAVR, SAVR patients are getting longer and longer

The study’s authors tracked data from more than 22,000 patients with severe aortic stenosis.

Thumbnail

Among TAVR patients with AFib, DOACs lead to better survival rates than vitamin K antagonists

However, the two treatment options were associated with similar rates of long-term bleeding and ischemic events. 

Thumbnail

New meta-analysis compares early TAVR outcomes for Sapien 3, Evolut valves—and spots some key differences

The new study focused on the early outcomes of more than 24,000 patients who participated in a total of nine different studies.

Thumbnail

Embolic protection devices fail to limit death or stroke among TAVR patients

The meta-analysis, published in the American Journal of Cardiology, explored data from six different randomized trials. 

Thumbnail

American College of Cardiology shares new guidance on TAVR-related conduction disturbances

The new guidance was designed to help clinicians provide high-quality care before, during and after TAVR procedures. 

Displaying 425 - 432 of 469

Around the web

Radiology Business
The impact of Trump tariffs on iodine contrast media costs

GE HealthCare said the price of iodine contrast increased by more than 200% between 2017 to 2023. Will new Chinese tariffs drive costs even higher?

Radiology Business
Key takeaways from RSNA 2024 for AI, CT, MRI and the radiology staffing shortage

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.